You have no items in your cart.
Kaftrio Approved for Children Ages 6 and Up in European Union, UK

The European Commission has expanded its approval of Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to treat children with cystic fibrosis (CF) as young as 6 who have the most common type of CF-causing mutation. The Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. approved a similar expansion. “Today both the European Commission and MHRA have agreed to license Kaftrio for use in children aged 6–11 years old. More than 1,500 children across the UK and…